Government Decree 212/2020  (as in force on  17 May 2020)  
This document has been produced for informational purposes only.  
1 Government Decree 212/2020 (16 May)  
on public health compulsory licences for exploitation within Hungary  
The Government,  
acting within its original legislative power laid down in Article 53  (2) of the Fundamental 
Law, having regard to the provisions of Act XII of 2020 on the containment of coronavirus,  
acting, with respect to section  7, within its original legislative power laid down in Article 
53 (3) of the Fundamental Law, on the  basis of authorisation by the National Assembly under 
section  3 (1) of Act  XII of  2020 on the containment of coronavirus,  
acting within its function laid down in Article 15  (1) of the Fundamental Law,  
decrees as follows:  
Section  1 (1) With a view to satis fying the needs arising within Hungary in connection with 
the health crisis as defined by section 228  (2) of Act  CLIV  of 1997 on healthcare, the Hungarian 
Intellectual Property Office (hereinafter “HIPO”) shall issue a public health compulsory licence 
(hereinafter “public health compulsory licence”) for the exploitation of  
a) a medicinal product or an active substance under patent or supplementary protection, or a 
medical device or an investigational medicinal product under patent protection (hereinafter 
jointly “healthcare product”), or  
b) a procedure, equipment or tool under patent protection that is required for the production 
of a healthcare product.  
(2) On the basis of a public health compulsory licence, the compulsory licence holder shall 
be entitled  to exploit the healthcare product, procedure, equipment or tool solely for satisfying 
the needs arising within Hungary as set out under paragraph  (1). 
(3) The public health compulsory licence shall not confer exclusive right of exploitation; on 
the basis of the public health compulsory licence, the public health compulsory licence holder 
may not grant any licence for exploitation.  
(4) The HIPO shall determine the period of a public health compulsory licence based on 
information provided by the pharmaceutic al state administration organ and having regard to the 
needs suitable for the management of the health crisis, with the proviso that the period for which 
a public health compulsory licence is granted shall not last longer than until 31 March 2021.  
(5) The pharmaceutical state administration organ shall issue the certificate regarding the 
supply need under paragraph  (4) at its own discretion, based on the analysis of information on 
the amount of supplies available and the assessment of risks. To acquire furt her data required 
for issuing the certificate, the pharmaceutical state administration organ may contact also the 
administrator of the National Healthcare Reserve or the Ministry led by the Minister responsible 
for healthcare for data provision.  
(6) For a public health compulsory licence, the patent holder shall be entitled to an appropriate 
fee. The fee shall be determined by the HIPO. The fee shall reflect the economic value of the 
public health compulsory licence and, in particular, it shall be proportio nate to the fee that the 
public health compulsory licence holder should pay on the basis of a licensing contract 
concluded with the patent holder, having regard to the conditions of licence trade established 
in the technological sector of the invention.  
(7) When determining the fee under paragraph  (6), the HIPO shall take into account, in 
particular,  
a) the typical rate of exploitation fees and net sales in the industrial sector concerned and  
b) the rate of the contribution of the use of the patent under pu blic health compulsory licence 
to the economic advantage manifest in the healthcare product, or in the procedure, equipment Government Decree 212/2020  (as in force on  17 May 2020)  
This document has been produced for informational purposes only.  
2 or tool under patent protection that is required for the production of a healthcare product (patent 
contribution rate).  
(8) The public health compulsory licence holder may renounce the public health compulsory 
licence at any time, by means of a declaration addressed to the HIPO. The HIPO shall notify 
the patent holder and the pharmaceutical state administration organ of the renunci ation.  
(9) The public health compulsory licence shall terminate upon renunciation, the expiry of the 
fixed period under paragraph  (4) or the termination of the supplementary protection.  
(10) In case the public health compulsory licence is terminated due to  renunciation or the 
expiry of the fixed period under paragraph  (4), the pharmaceutical stated administration organ 
shall order, by way of a decision, the destruction of the healthcare product, or the procedure, 
equipment or tool required for the productio n of a healthcare product, that has not been lawfully 
placed on the market by the public health compulsory licence holder.  
(11) Paragraph  (10) shall not apply if, before the expiry of the fixed period under 
paragraph  (4), the public health compulsory licen ce holder acquires a new public health 
compulsory licence with the same material scope as the public health compulsory licence 
serving as basis for the production of the healthcare products.  
(12) If placing on the market of a healthcare product produced on  the basis of a public health 
compulsory licence is conditional, by virtue of an Act, upon a permit issued by an authority, in 
the course of its permission procedure, when deciding on an application, the authority of 
permission shall regard the content of the public health compulsory licence as having been 
proven.  
Section  2 (1) Healthcare products produced on the basis of a public health compulsory 
licence shall be distinguished from products produced by the patent holder by a unique marking. 
The fact that a healthcare product was produced on the basis of a public health compulsory 
licence granted by the HIPO for the sole purpose of placing it into market in Hungary shall be 
clearly indicated on the packaging and any related documents.  
(2) The pharmaceutical  state administration organ shall oblige public health compulsory 
licence holders who fail to fulfil their obligation under paragraph  (1) to repackage the healthcare 
products in compliance with paragraph  (1) and section  3 (2) c). 
(3) In accordance with sec tion 35 (3) of Act XXXIII  of 1995  on the protection of inventions 
by patents (hereinafter “Szt.”), a patent holder may claim damages for the unauthorised use of 
a healthcare product, or a procedure, equipment or tool that is required for the production of a 
healthcare product, under patent protection. This provision shall apply to supplementary 
protection accordingly.  
Section  3 (1) To the procedure relating to public health compulsory licences, the provision of 
the Szt. shall apply subject to the following  derogations:  
a) the HIPO shall proceed in a panel of three,  
b) for the remedy of deficiency or the making of statements, a time limit not shorter than 
fifteen days, but not longer than thirty days, shall be set, and extensions of time limits may be 
granted only in particularly justified cases,  
c) the HIPO shall proceed as a matter of priority.  
(2) In addition to the requirements specified in section  45 (5) and (6) of the Szt., an 
application for a public health compulsory licence shall contain the fo llowing:  
a) the registration number of the patent or supplementary protection certificate granted for the 
invention to be exploited on the basis of the public health compulsory licence,  
b) the name of the healthcare product, or the non -proprietary name of a medicinal product, 
the applicant wishes to produce on the basis of the compulsory licence,  Government Decree 212/2020  (as in force on  17 May 2020)  
This document has been produced for informational purposes only.  
3 c) the markings distinguishing the healthcare product to be produced on the basis of the public 
health compulsory licence from the products of the patent holder, i n accordance with 
section  2 (1), 
d) a certificate by the pharmaceutical state administration organ certifying that the applicant 
applies for a public health compulsory licence for a healthcare product suitable for satisfying 
the needs arising within Hungar y in connection with the health crisis in a necessary amount, as 
set out in the certificate,  
e) a certificate that the applicant for a public health compulsory licence has the capacity 
required for the production of the amount to be produced on the basis of the public health 
compulsory licence as specified in the certificate under point d), 
f) if the  requirements set out in point e) are not met, a certificate that the applicant made 
substantive preparations to secure the capacity required for the production of the amount 
specified in the certificate under point d). 
(3) The submission of an application  for public health compulsory licence shall be subject to 
a fee as set out in the law on administrative service fees in industrial property procedures. In 
the case of a failure to pay such fee, the application shall be deemed withdrawn.  
(4) After the recei pt of an application, the HIPO shall examine whether  
a) the application meets the conditions set out in paragraphs  (2) and (3), 
b) the conditions set out in section  1 (1) are met.  
(5) Within eight days following the receipt of an application, the HIPO shal l notify the patent 
holder concerned of the fact that an application for compulsory licence was submitted regarding 
his invention.  
(6) Any infringement proceedings against the applicant for a public health compulsory licence 
related to the patent, or suppl ementary protection certificate, specified in the application, or any 
provisional measures connected thereto, shall be suspended until the decision by the HIPO.  
(7) If an application for a public health compulsory licence does not meet the conditions set 
out in paragraph  (4), the applicant shall be called upon to remedy the deficiencies or to make a 
statement. The application shall be rejected if it fails to meet the examined requirements, even 
after the remedy of deficiencies or the making of a statement. If the applicant fails to respond 
to a notice to remedy deficiencies within the time limit set, the application shall be deemed 
withdrawn.  
Section  4 (1) The HIPO shall decide on granting a public health compulsory licence or 
rejecting an application withou t conducting a hearing. The decision shall be put in writing and 
communicated to the applicant. The HIPO shall notify the patent holder of the decision within 
eight days following the making of the decision.  
(2) A decision granting a public health compulso ry licence shall include the following:  
a) the period of the public health compulsory licence,  
b) the characteristics distinguishing the healthcare product to be produced on the basis of the 
public health compulsory licence from the product of the patent holder,  
c) the fee payable to the patent holder,  
d) the registration number of the patent or the supplementary protection certificate, and  
e) the name of the healthcare product or the non -proprietary name of a medicinal product. 
(3) A public health compuls ory licence shall be registered in the register of patents or 
supplementary protection certificates and an official notice thereon shall be published in the 
official journal of the HIPO about it.  
(4) The HIPO shall notify the pharmaceutical state administr ation organ of granting a public 
health compulsory licence without delay.  Government Decree 212/2020  (as in force on  17 May 2020)  
This document has been produced for informational purposes only.  
4 Section  5 (1) To legal remedies against a decision of the HIPO under section  4 (1), the 
provisions of the Szt. shall apply, with the proviso that an application for modification shal l 
have no suspensory effect regarding a public health compulsory licence granted.  
(2) During the period of the compulsory licence, an interim relief shall not be allowed in an 
action brought against a decision concerning a medicinal product produced on the  basis of the 
compulsory licence.  
Section  6 (1) With the exception specified in paragraph  (2), this Decree shall enter into force 
on the day following its promulgation.  
(2) Section  7 shall enter into force on the fifteenth day following the promulgation of  this 
Decree.  
Section  7